In addition, the class of fusion-protein inhibitors (led by Enbrel) will see its sales almost tripled from $2,299m in 2004 to $6,366m in 2010, while its market shares will grow from 7% to 12%.

Enbrel, a recombinant fusion protein that blocks tumor necrosis factor, is used to treat rheumatoid arthritis and psoriasis, and generated $1.69 billion in US sales for Amgen in the first half of ...

Etanercept (Enbrel ®) is an injectable fusion protein that competitively inhibits the pro-inflammatory cytokine TNF-α. It is approved for use in rheumatoid arthritis, juvenile rheumatoid ...

The appeals court ruling blocks Sandoz from producing a biosimilar of Enbrel (etanercept) until 2029, more than thirty years after it was first approved. Sandoz, which is the biosimilars and ...

Amgen’s venerable TNF inhibitor Enbrel (etanercept) for arthritis and other inflammatory conditions topped the list of offenders in terms of the added cost to the healthcare system, which ICER ...